Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry
We sought to determine the efficacy of a new, inexpensive, single-tube 8-color multiparameter flow cytometry (MFC) method (SRL-Flow), which is based on the EuroFlow next-generation flow (NGF) (tube 2 only), to assess minimal residual disease (MRD)-negative status. MRD-negative status is considered a treatment milestone in multiple myeloma (MM). We used 45 bone marrow samples from patients with MM, including 11 cases treated with anti-CD38 monoclonal antibody. The SRL-Flow sample preparation protocol was identical to that of EuroFlow-NGF. The antibody panel for SRL-Flow was as follows: CD138V450/CD27V500/CD38ME (multiepitope)FITC/CD56PE/CD45PerCP-Cy5.5/CD19PE-Cy7/cytoplasmic (Cy) immunoglobulin (Ig) κAPC/CyIgλAPC-H7. To identify abnormal plasma cells (aPCs) of patients with MM who received anti-CD38 monoclonal antibody, we used a panel of anti-CD45 and anti-CD138 antibodies (Abs) rather than a panel of anti-CD45 and anti-CD38 Abs. We comparatively analyzed the total nucleated cell numbers, total PC levels, and MRD levels between the SRL-Flow and EuroFlow-NGF. High correlations (r > 0.9) in total PC and MRD levels were noted among SRL-Flow, original EuroFlow-NGF (2 tubes), and EuroFlow-NGF (tube 2 only), suggesting that SRL-Flow is an inexpensive (< $200 USD/sample as of January of 2019) alternative to EuroFlow-NGF (< $350 USD/sample) for assessing MRD in MM.
KeywordsMyeloma Minimal residual disease Multiparameter flow cytometry EuroFlow
We would like to acknowledge Dr Juan Flores-Montero, Dr Luzalba Sanoja-Flores and Prof Alberto Orfao of Universidad de Salamanca for the EuroFlow-NGF assessments.
HT conceived and designed the study; HT, TY, MF, KK, MH, TY, RM, MU, SN and KM acquired the data; HT, TY, KK, MH, and KM assembled, analyzed and interpreted the data; HT wrote the manuscript; and all authors reviewed the manuscript.
Compliance with ethical standards
Conflict of interest
H.T. and K.M. received research funding from SRL, Inc. K.K. and M.H. are employees of SRL, Inc. The remaining authors declare no competing financial interests.